Insulin resistance improving agent

A technology of insulin resistance and improving agent, applied in the direction of organic active ingredients, metabolic diseases, drug combination, etc., to achieve the effect of improving insulin resistance

Inactive Publication Date: 2007-04-25
MITSUBISHI TANABE PHARMA CORP
View PDF15 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] As far as the inventors of the present invention are aware, there has not been any report so far on the improvement of insulin resistance exhibited by pharmaceutically acceptable anion exchange resins

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Insulin resistance improving agent
  • Insulin resistance improving agent
  • Insulin resistance improving agent

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0079] 1. Test method

[0080]ApoE3 Leiden mice (male, TNO Pharma, Leiden, The Netherlands) (n=45) were fed a high-fat diet (45.4% fat) for three weeks, according to body weight and serum parameters (total cholesterol (TC), triglyceride Value (TG), blood glucose level (Glc)) were divided into two groups, one group (n=30) continued to be fed with high-fat food (high-fat food group) as it was, and the other group (n=15) was given high-fat food Foods containing 1.5 (w / w)% cholemide in (cholemide prevention group).

[0081] After 12 weeks, the high-fat food group was further divided into two groups according to the aforementioned body weight and serum parameters (TC, TG, Glc), one group was the high-fat food group (control group, n=15), and the other group was given high-fat food group. Diets containing 1.5 (w / w) % cholemide in fatty food (cholemide treatment group, n=15).

[0082] Eight weeks later, insulin resistance was determined using a hyperinsulinemic clamp. The animal w...

Embodiment 2

[0102] 1. Test method

[0103] KKAy mice (male, Nippon CLEA, n=8) were used. The control group was fed a high-fat diet (23.6% fat), and the cholemide group was fed a high-fat diet containing 2% cholemide. In the second week after the administration, the glucose tolerance test was carried out according to the conventional method. The mice were fasted overnight, blood was collected before glucose tolerance, and then glucose solution was orally administered, and blood glucose levels were measured 30, 60, 90, and 120 minutes later. The blood glucose value AUC (0-120 minutes) was calculated by using the obtained blood glucose value. Fasting blood glucose and fasting insulin values ​​were measured using blood samples before glucose tolerance.

[0104] 2. Results

[0105] (1) fasting blood sugar level

[0106] Figure 8-1 shows the fasting blood glucose values ​​of the control group and the colemide group. The fasting blood glucose level of the colemide group was significantly l...

Embodiment 3

[0113] 1. Test method

[0114] KKAy mice (male, Nippon CLEA, n=8) were used. The control group was fed with high-fat diet (23.6% fat), and the colesevelam hydrochloride group was fed with high-fat diet containing 2% colesevelam hydrochloride. In the second week after the administration, the glucose tolerance test was carried out according to the conventional method. The mice were fasted overnight, blood was collected before glucose tolerance, and then glucose solution was orally administered, and blood glucose levels were measured 30, 60, 90, and 120 minutes later. The blood glucose value AUC (0-120 minutes) was calculated by using the obtained blood glucose value. Fasting blood glucose and fasting insulin values ​​were measured using blood samples before glucose tolerance.

[0115] 2. Results

[0116] (1) fasting blood sugar level

[0117] Figure 9-1 shows the fasting blood glucose values ​​of the control group and colesevelam hydrochloride group. The fasting blood gluc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A medical agent capable of exhibiting an insulin resistance improving activity without being influenced by a diet or sugar absorption through the gastrointestinal tract, which medical agent comprises a pharmacologically acceptable anion exchange resin as an active ingredient.

Description

technical field [0001] The invention relates to an insulin resistance improving agent which takes a pharmaceutically acceptable anion exchange resin as an active ingredient. Background technique [0002] With regard to anion exchange resins known as cholesterol-lowering agents represented by colestimide (trade name: CHOLEBINE, Mitsubishi Pharmaceutical Co., Ltd.), it has been reported so far that blood glucose decreased (Non-Patent Document 1), and it has been reported that it also has an impact on the diurnal variation of blood sugar in hypercholesterolemia patients with type 2 diabetes (Patent Document 1). However, its mechanism of action has not been clarified. For example, it has been reported that cholestyramine resin has a hypoglycemic effect (non-patent literature 2), but the mechanism is not the improvement of insulin resistance, but because it inhibits the digestion mediated by CCK tract movement and promote insulin secretion. [0003] For insulin preparations, t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/785A61K31/74A61K31/787A61K45/00A61P3/06A61P3/10A61P5/50A61P9/00A61P9/10A61P9/12A61P13/12A61P19/06
CPCA61K31/785A61K31/787A61K31/74A61P1/16A61P13/12A61P19/06A61P3/10A61P3/06A61P5/50A61P9/00A61P9/10A61P9/12
Inventor 铃木一夫中岛成和杉本佳奈美
Owner MITSUBISHI TANABE PHARMA CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap